American Society of Hematology, 2025 (ASH) 7 - 9 December 2025

Etavopivat in Adolescents with Sickle Cell Disease: Emerging Safety and Efficacy Findings from the First Cohort of the Ongoing Phase 1/2 HIBISCUS Kids Study

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Sickle Cell Disease
Congress oral presentation
Etavopivat